🏛️ Verified NIH Record • Updated 2025-05-29
COVID-19 Vaccine Responses in PIDD Subjects (NCT05321407)
Vaccine-induced SARS-CoV-2-specific T Cell Responses in Patients With Primary Immune Deficiency Disease
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Duke University
🩺 Plain-English Summary (8th-Grade Level)
The goal of our study is to assess the cellular immune responses of participants with antibody deficiency disease before and after immunization with SARS-CoV-2 mRNA vaccines.
Who can join: Review the eligibility criteria below.
Location: University of South Florida — St. Petersburg, Florida
Age range: 6 Months
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of South Florida — St. Petersburg, Florida
- University of North Carolina, Chapel Hill — Chapel Hill, North Carolina
- Duke University — Durham, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All X-linked Agammaglobulinemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.